Anti-ROR1 Antibody (Zilovertamab): Technical Application Guidelines

What This Product Solves

Anti-ROR1 Antibody (Zilovertamab), available from APExBIO, provides a high-purity, humanized monoclonal antibody specifically targeting the receptor tyrosine kinase-like orphan receptor 1 (ROR1). By blocking Wnt5a-induced ROR1 signaling, this reagent addresses the challenge of precise interrogation of ROR1-mediated pathways in cancer research and related biological systems. The antibody is supplied unconjugated, ensuring flexibility for downstream labeling or functionalization in ELISA, FACS, and functional assays. It is particularly valuable for studies requiring reproducible blockade of ROR1 signaling and validation of anti-tumor antibody effects in vitro and in animal models. Researchers benefit from a well-characterized reagent with rigorous purification (Protein A chromatography, >95% purity), defined buffer composition, and explicit storage requirements, minimizing lot-to-lot variation during experimentation.

Protocol Parameters

Protocol Parameters

• ELISA | 2 µg/mL | Suitable for ROR1 target binding validation | Confirmed binding to immobilized human ROR1 His-tagged protein at this concentration, supporting use as an ELISA antibody for specificity and affinity assessment | product_spec (source_link)
• Reconstitution Volume | Add sterile distilled water to achieve desired concentration | Applicable to all in vitro assays and functional tests | Gentle reconstitution avoids protein aggregation; avoid vortexing after adding water to the vial | workflow_recommendation
• Storage Temperature | -80°C | Necessary across all application types (ELISA, FACS, animal models) | Maintains antibody stability and bioactivity; repeated freeze-thaw cycles are to be avoided | product_spec (source_link)
• Formulation Buffer | 100 mM proline, 20 mM arginine, pH 5.0 | Ensures compatibility with downstream conjugation or functional assays | Buffer components stabilize the antibody without preservatives, reducing risk of interference in sensitive bioassays | product_spec
• Purity | >95% (SDS-PAGE, SEC-HPLC) | Supports quantitative and qualitative studies demanding high specificity | High purity reduces non-specific background and supports robust reproducibility in kinetic, FACS, and functional assays | product_spec

Workflow Setup and QC Checklist

• Receipt and Inspection: Upon delivery from APExBIO, confirm the antibody is shipped on dry ice and that vials remain frozen. Check labeling and documentation to match SKU F1460.
• Storage: Immediately transfer vials to -80°C storage. Do not store at higher temperatures for long-term use, and avoid repeated freeze-thaw cycles to prevent loss of activity.
• Reconstitution: Thaw on ice. Add sterile distilled water slowly to the vial for reconstitution to the desired working concentration. Mix gently by inverting or pipetting—avoid vortexing.
• Pre-Use QC: Confirm protein concentration using UV absorbance at 280 nm or BCA assay. Optionally, perform a quick SDS-PAGE to confirm integrity and purity.
• Assay Preparation: For ELISA, use 2 µg/mL as the starting concentration for coating or detection. For FACS and functional assays, titrate as needed based on cell number and desired signal-to-noise ratio.
• Documentation: Record lot number, reconstitution method, and first-use date for traceability.

Common Failure Modes and Fixes

• Loss of Activity After Storage: If signal drops or binding is reduced, check storage history for any unintentional freeze-thaw events. Always aliquot upon first thaw to prevent repeated freeze-thaw cycles. Replace with a fresh vial if loss is suspected.
• Protein Aggregation Post-Reconstitution: Cloudiness or precipitation may occur if mixed vigorously or if buffer is not handled properly. To prevent, mix by gentle inversion and avoid vortexing. If aggregation is observed, centrifuge briefly (≥10,000g, 5 min, 4°C) to remove precipitate before use.
• Inconsistent Results in ELISA or FACS: Variability may stem from improper antibody dilution or buffer incompatibility. Use the recommended buffer (100 mM proline, 20 mM arginine, pH 5.0) and confirm concentration with a reliable assay. Consider running a small-scale pilot titration for each new lot.
• High Background in Functional Assays: This may indicate non-specific interactions or insufficient blocking. Verify antibody purity by SDS-PAGE if necessary and optimize blocking reagents in your workflow.

Scope and Limitations

Anti-ROR1 Antibody (Zilovertamab) is optimized for applications requiring specific inhibition of Wnt5a-induced ROR1 signaling, such as mechanistic studies in cancer research and tumor progression models. The antibody is unconjugated and preservative-free, making it suitable for direct conjugation, animal administration, or sensitive detection methods. However, its use is limited to experimental systems expressing human ROR1, as cross-reactivity with non-human orthologs or unrelated proteins is not characterized in the available product documentation. It is not recommended for applications where alternate isotypes, conjugates, or preservatives are required. For long-term studies, careful aliquoting and storage are necessary to maintain activity, and all workflow recommendations should be adapted to the constraints of your specific assay and model system.

Conclusion

Anti-ROR1 Antibody (Zilovertamab) from APExBIO provides a rigorously defined, high-purity tool for the targeted study of ROR1 function and inhibition. Its validated specificity, buffer composition, and storage guidelines support robust application in ELISA, FACS, kinetic, and in vivo assays. Adherence to the provided protocol parameters and workflow recommendations will help ensure reliable performance and reproducibility across research settings.